Dosimetric and Clinical Outcomes of Involved-Field Intensity-Modulated Radiotherapy after Chemotherapy for Early-Stage Hodgkin’s Lymphoma with Mediastinal Involvement

Ning-Ning Lu,Ye-Xiong Li,Run-Ye Wu,Xi-Mei Zhang,Wei-Hu Wang,Jing Jin,Yong-Wen Song,Hui Fang,Hua Ren,Shu-Lian Wang,Yue-Ping Liu,Xin-Fan Liu,Bo Chen,Jian-Rong Dai,Zi-Hao Yu
DOI: https://doi.org/10.1016/j.ijrobp.2011.11.008
2012-01-01
Abstract:Purpose: To evaluate the dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy (IF-IMRT) for patients with early-stage Hodgkin's lymphoma (HL) with mediastinal involvement.Methods and Materials: Fifty-two patients with early-stage HL that involved the mediastinum were reviewed. Eight patients had Stage I disease, and 44 patients had Stage II disease. Twenty-three patients (44%) presented with a bulky mediastinum, whereas 42 patients (81%) had involvement of both the mediastinum and either cervical or axillary nodes. All patients received combination chemotherapy followed by IF-IMRT. The prescribed radiation dose was 30-40 Gy. The dose-volume histograms of the target volume and critical normal structures were evaluated.Results: The median mean dose to the primary involved regions (planning target volume, PTV1) and boost area (PTV2) was 37.5 Gy and 42.1 Gy, respectively. Only 0.4% and 1.3% of the PTV1 and 0.1% and 0.5% of the PTV2 received less than 90% and 95% of the prescribed dose, indicating excellent PTV coverage. The median mean lung dose and V20 to the lungs were 13.8 Gy and 25.9%, respectively. The 3-year overall survival, local control, and progression-free survival rates were 100%, 97.9%, and 96%, respectively. No Grade 4 or 5 acute or late toxicities were reported.Conclusions: Despite the large target volume, IF-IMRT gave excellent dose coverage and a favorable prognosis, with mild toxicity in patients with early-stage mediastinal HL. (C) 2012 Elsevier Inc.
What problem does this paper attempt to address?